Osteoporosis: From bone biology to individual treatment decision;Osteoporose: Da biologia óssea à decisão terapêutica individual

Acta Medica Portuguesa

Volumn 26, Issue 4, 2013, Pages 445-455

  Gonçalves, Maria João ^a,b   Rodrigues, Ana Maria ^a,c   Canhão, Helena ^a,b   Fonseca, João Eurico ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c Hospital Santo Espirito de Angra do Heroesmo   (Portugal)

Author keywords

Bone and bones; Bone remodeling; Bone resorption; Osteoblasts; Osteoclasts; Osteoporosis epidemiology; Osteoporosis therapy

Indexed keywords

ALENDRONIC ACID; BA 058; BETA CATENIN; CALCITONIN; CALCITRIOL; CALCIUM SENSING RECEPTOR; CATHEPSIN K; COLLAGEN TYPE 1; DENOSUMAB; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; IBANDRONIC ACID; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SCLEROSTIN; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DENSITY; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DIARRHEA; DIZZINESS; DRESS SYNDROME; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; ESOPHAGUS CANCER; FEMUR NECK; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IMMUNE SYSTEM; JAW OSTEONECROSIS; MUSCULOSKELETAL PAIN; NAUSEA; OBESITY; ORTHOSTATIC HYPOTENSION; OSSIFICATION; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN INFECTION; SPINE FRACTURE; SUBSTITUTION THERAPY; UROLITHIASIS; VENOUS THROMBOEMBOLISM;

BONE AND BONES; FRACTURES, SPONTANEOUS; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84883504134     PISSN: 0870399X     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Khaltaev N, Pfleger BA, on behalf of WHO, WHO Scientific Group on the Assessment of Osteoporosis at the Primary Health Care Level meeting, Summary Meeting Report, Brussels, Belgium, 5-7 May 2004. WHO 2007. [Accessed 2013 Jun 02]. Disponível em: http://www.who.int/chp/topics/Osteoporosis.pdf.
2. Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ. Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc. 2010;58:650-7.
3. Branco JC, Felicíssimo P, Monteiro J. A epidemiologia e o impacto sócio-económico das fracturas da extremidade proximal do fémur, uma reflexão sobre o padrão actual de tratamento da osteoporose grave. Acta Reumatol Port. 2009;34:475-85.
4. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38:S4-9.
5. Cooper C, Zole CA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22:1277-88.
6. Cauley JA, Newman AB. Osteoporosis. In: Newman AB, Cauley JA, editors. The Epidemiology of Aging. Amsterdam: Springer; 2012. p. 499-522.
7. von Friesendorff M, Besjakov J, Akesson K. Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res. 2008;23:1832-41.
8. Andrew T, Antioniades L, Scurrah KJ, MacGregor AJ, Spector TD. Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J Bone Miner Res. 2005;20:67-74.
9. Center JR, Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-82.
10. Christiansen C. Consensus development conference (1993): Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646-50.
11. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
12. Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22:2789-98.
13. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195-202.
14. Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92:743-53.
15. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420.
16. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-87.
17. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-36.
18. Siris E, Miller P, Barrett-Connor E, Abbott T, Sherwood L, Berger M. Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. Osteoporos Int.1998;8:S62-9.
19. Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (Bisphophonates, Parathyroid Hormone, Strontium Ranelate and Denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010;87:469-84.
20. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97.
21. Marques A, Mota A, Canhão H, Romeu JC, Machado P, Ruano A, et al. A FRAX model for the estimation of osteoporosis fracture probability in Portugal. Acta Reumatol Port. 2013;38:104-12.
22. Cummins NM, Poku EK, Towler MR, O'Driscoll OM, Ralston SH. Clinical risk factors for osteoporosis in Ireland and the UK: a comparison of Frax and QFractures Scores. Calcif Tissue Int. 2011;89:172-7.
23. Baccheta J, Boutroy S, Vilayphiou N, Juillard L, Guebre-Egziabher F, Rognant N, et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV Chronic Kidney Disease. J Bone Miner Res. 2010;25:849-57.
24. Nickolas TL, Leonard MB, Shane E. Chronic Kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74:721-31.
25. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab. 1992;75:45-51.
26. Brzozowska MM, Sainsbury A, Eisman JA, Baldock PA, Center JR. Bariatric surgery, bone loss, obesity and possible mechanisms. Obes Rev. 2013;14:52-67.
27. Gilsanz V, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD. Reciprocal Relations of Subcutaneous and Visceral Fat to Bone Structure and Strength. J Clin Endocrinol Metab. 2009;94:3387-93.
28. Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, et al. Correlation of Obesity and Osteoporosis: Effect of Fat Mass on the Determination of Osteoporosis. J Bone Miner Res. 2008;23:17-29.
29. Rodrigues AM, Caetano-Lopes J, Vale AC, Vidal B, Lopes A, Aleixo I, et al. Low osteocalcin/collagen type I bone gene expression ratio is associated with hip fragility fractures. Bone. 2012;51:981-9.
30. Rodrigues AM, Caetano-Lopes J, Vale AC, Aleixo I, Pena AS, Faustino A, et al. Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patients. J Bone Miner Metab. 2012;30:692-9.
31. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol. 2008;61:577-7.
32. Kim JH, Liu X, Wang J, Chen X, Zhang H, Kim SH, et al. Wnt signalling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskel Dis. 2013;5:13-31.
33. Caetano-Lopes J, Lopes A, Rodrigues A, Fernandes D, Perpetuo IP, Monjardino T, et al. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. Plos One. 2011;6:e16947.
34. Manolagas SC. Birth and death of bone cells: basic regulatory, mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-37.
35. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-22.
36. Amizuka N, Li M, Kobayashi M, Hara K, Akahane S, Takeuchi K, et al. Vitamin K2, a gamma-carboxylating factor of gla-proteins, normalizes the bone crystal nucleation impaired by Mg-insufficiency. Histol Hispathol. 2008;23:1353-66.
37. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. Nature. 2012;485:69-74.
38. Caetano-Lopes J, Canhão H, Fonseca JE. Osteoimmunology - the hidden imune regulation of bone. Autoimmun Rev. 2009;8:250-5.
39. Zupan J, Matjaz J, Marc J. Osteoimmunology and the influence of proinflamatory cytokines on osteoclast. Biochem Med. 2013;1:43-65.
40. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodelling. Nat Med. 2007;13:156-63.
41. Caetano-Lopes J, Nery AM, Canhão H, Duarte J, Cascão R, Rodrigues A, et al. Chronic arthritis leads to disturbances in the bone collagen network. Arthritis Res Ther. 2010;12R9.
42. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002;17:200-9.
43. Jackson MA, Iwaniec UT, Turner RT, Wronski TJ, Kalra SP. Effects of increased hypothalamic leptin gene expression on ovariectomy-induced bone loss in rats. Peptides. 2011;32:1575-80.
44. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309:99-109.
45. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21:1648-56.
46. Wong I, Driessler F, Khor EC, Shi Y, Nguyen AD, Enriquez RF, et al. Peptide YY regulates bone remodeling in mice: a link between gut and skeletal biology. PlosONE. 2012;7:e40038.
47. Costa JL, Naot D, Lin JM, Watson M, Callon KE, Reid IR, et al. Ghrelin is an osteoblast mitogen and increases osteoclastic bone resorption in vitro. Int J Pept. 2011;2011:605193.
48. Baldock PA, Sainsbury A, Allison S, Lin EJ, Couzens M, Boey D, et al. Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res. 2005;20:1851-7.
49. Florent E. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 2008;473:231-6.
50. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology. 2009;48:iv3-8.
51. Burghardt AJ, Link TM, Majumdar S. High-resolution computed tomography for clinical imaging of bone microarchitecture. Clin Orthop Relat Res. 2011;469:2179-93.
52. Amin S, Khosla S. Sex and age-related differences in bone microarchitecture in men relative to women assessed by high-resolution peripheral quantitative computed tomography. J Osteoporos. 2012;2012:129760.
53. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009;20:843-51.
54. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-36.
55. Chapurlat RD, Garnero P, BreArt G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (Serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone. 2000;27:283-6.
56. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res. 2005;20:579-87.
57. Vidal B, Galvão MJ, Santos AR, Rodrigues A, Cascão R, Abdulghani S, et al. Bone histomorphometry revisited. Acta Reumatol Port. 2012;37:294-300.
58. Kanis JA, McCloskey EV, Johanson H, Cooper C, Rizzoli R, Reginster JY. European Guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23-57.
59. Tavares V, Canhão H, Melo-Gomes JA, Simões E, Romeu JC, Coelho P, et al. Recomendações para o diagnóstico e terapêutica da osteoporose, Sociedade Portuguesa de Reumatologia e Sociedade Portuguesa de Doenças Ósseas Metabólicas. Acta Reumatol Port. 2007;32:49-59.
60. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19:1395-408.
61. Cosman F, Lindsay R, LeBoff MS, de Beur SJ, Tanner B. National Osteoporosis Foundation, Clinician's guide to prevention and treatment of osteoporosis 2013. [Accessed 2013 Jun 02]. Disponível em: http://www.nof.org/files/nof/public/content/resource/913/files/580.pdf).
62. Branco JC, Tavares V, Vaz AF, Simões E, Canhão H, George F. Tratamento Farmacológico da Osteoporose Pós-menopáusica, Norma da direcção geral de saúde. 027/2011. [Accessed 2013 Jun 02]. Disponível em: http://www.dgs.pt/?cr=21174.
63. Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemare S, et al. Extraskeletal benefits and risk of calcium, vitamin D and antiosteoporosis medications. Osteoporos Int. 2012;23:S1-23.
64. Saraví FD, Sayegh F. Bone mineral density and body composition of adult premenopausal women with three levels of physical activity. J Osteoporos. 2013;2013:953271.
65. Järvinen TN, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008;336:124-6.
66. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5:65-74.
67. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-43.
68. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner TN, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA. 1999;282:1344-52.
69. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22.
70. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-9.
71. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment. JAMA. 2006;296:2927-37.
72. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effects of 3 versus 6 years if zoledronic Acid treatment of osteoporosis: a randomized extension to HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012;27:243-54.
73. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-For whom and for how long? N Engl J Med. 2012;366:2051-3.
74. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761-71.
75. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
76. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ. 2013;346:f114.
77. Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int. 2011;22:1659-67.
78. Reginster JY, Seeman E, de Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis. Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-22.
79. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
80. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX. Osteoporos Int. 2011;22:2347-55.
81. European Medicines Agency confirms positive benefit-risk balance of Protelos/Osseor, but recommends new contraindications and revised warnings, EMA/CHMP/185175/2012 (March 2012). [Accessed 2013 Jun 02]. Disponível em: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/03/WC500124206.pdf.
82. Pharmacovigilance Risk Assessment Committee (PRAC) recommends restriction in the use of Protelos/Osseor, EMA/220628/2013 (April 2013). [Accessed 2013 Jun 02]. Disponível em: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000560/WC500142021.pdf.
83. Bodenner D, Redman D, Riggs A. Teriparatide in the management of osteoporosis. Clin Interv Aging. 2007;2:499-507.
84. Cummings SR, San-Martin J, McClung MR, Siris ES, Eastel R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
85. Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72-81.
86. Miller PD. A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis. 2011;3:271-82.
87. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, Mc-Clung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26:1829-35.
88. Gianni W, Ricci A, Gazzaniga P, Brama M, Pietropaolo M, Votano S, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab. 2004;89:6097-9.
89. Taranta A, Brama M, Teti A, DeLuca V, Scandurra R, Spera G, et al. The selective estrogen receptor modulator raloxifene regulates osteoblast and osteoclast activity in vitro. Bone. 2002;30:368-76.
90. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45.
91. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923-34.
92. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML. Risks and benefits of estrogen and progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321.
93. Zaidi M, Moonga BS, Abe E. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002;110:1769-71.
94. Questions and answers on the review of calcitonin-containing medicines, EMA/731082/2012, EMEA/H/A-31/1291 (November 2012). [Accessed 2013 Jun 02]. Disponível em: http://www.emea.europa.eu/docs/en_GB/document_library/Referrals_document/Calcitonin_31/WC500134838.pdf.
95. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42:4-15.
96. Rizzol R, Kraenzli M, Krieg MA, Mellinghoff HU, Lamy O, Lippuner K. Indications to teriparatide treatment in patients with osteoporosis. Swiss Med Wkly. 2011;141:w13297.
97. Murphy DR, Smolen LJ, Klein TM, Klein RW. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausalosteoporosis patients in Sweden. BMC Musculoskelet Disord. 2012;30:213.
98. Hiligsmann M, Vanoverberghe M, Neuprez A, Bruyère O, Reginster JY. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2010;10:359-66.
99. Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, et al. Cost-effectiveness of Denosumab for the treatment of postmeno-pausalosteoporosis. Osteoporos Int. 2011;22:967-82.
100. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011;22:2565-73.
101. Vivien L, Clarke BL. New therapeutics target for osteoporosis: beyond denosumab. Maturitas. 2012;73:269-72.
102. Kimura S, Nakagawa T, Matsuo Y, Ishida Y, Okamoto Y, Hayashi M. JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats. Eur J Pharmacol. 2011;668:331-6.
103. Roux C, Cooper C, Díez-Pérez A, Martinez L, Ortolani S, Gitlin M. Prevalence of osteoporosis and fractures among women prescribed osteoporosis medication in five European countries: the POSSIBLE EU® study. Osteoporos Int. 2011;22:1227-36.